Following promising preclinical results, two clinical trials have been established to investigate the therapeutic value of co-delivering immune checkpoint inhibitors with EGFRvIII-targeting and IL-13Rα2-targeting CAR T-cells in GBM patients (NCT03726515, NCT04003649) [246]. Here, IL13RA2 is linked to glioblastoma.